Tumor Angiogenesis in Different Organ Environments: Implications for Anti-VEGF Therapy for Soft Tissue Sarcomas

Anti-angiogenic agents targeting vascular endothelial growth factor (VEGF) and other angiogenic pathways are a major focus of clinical drug development for cancers including soft tissue sarcomas (STS). An underlying premise of these trials is that VEGF inhibition will have equal efficacy in all sites of tumor growth and against all types of endothelial cells. This proposal seeks to develop an angiogenic profile of STS growing in different organs and tissues and to determine if inhibition of VEGF signaling will have varying effects on tumor angiogenesis in differen